Upgrade to SI Premium - Free Trial

Esperion Therapeutics (ESPR) Misses Q2 EPS by 15c

August 8, 2019 7:38 AM
Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($2.01), $0.15 worse than the analyst estimate of ($1.86). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Earnings Management Comments

Next Articles